Myozyme (Alglucosidase Alfa)

Alglucosidase alfa is a recombinant human acid alpha‑glucosidase that replaces the deficient enzyme in Pompe disease. After intravenous infusion, it is taken up by cells via mannose‑6‑phosphate receptors, reaches lysosomes, and catalyzes the breakdown of accumulated glycogen into glucose, thereby decreasing cellular storage material.

The dosing regimen for Myozyme is individualized and set by the prescribing physician based on the patient’s age, weight, disease severity, and clinical response. Healthcare professionals calculate the appropriate amount and infusion schedule according to approved guidelines and patient monitoring.

Safety data for Myozyme in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Physicians should discuss the uncertainties with patients and consider alternative options when appropriate.

To order Myozyme, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Myozyme and Lumizyme contain the same recombinant enzyme (alglucosidase alfa) and are both approved for Pompe disease. Differences may lie in manufacturing processes, packaging, and regional regulatory status. Clinical efficacy is comparable, while safety profiles are similar; selection often depends on supply logistics and local approvals.

Myozyme must be stored refrigerated at 2‑8 °C. It should be protected from light, kept in its original container, and must not be frozen or shaken. Before use, the lyophilized powder is reconstituted with the supplied diluent under aseptic conditions for intravenous infusion.

Myozyme is administered as an intravenous infusion. The lyophilized powder is reconstituted with sterile diluent to the appropriate concentration, then infused over a period defined by the treating physician, typically ranging from 30 minutes to several hours depending on patient tolerance.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, cardiac events like arrhythmias or myocardial infarction, and renal impairment. Patients should be monitored closely during and after infusion for any signs of these adverse events, and emergency measures should be readily available.

Myozyme is contraindicated in patients with known hypersensitivity to alglucosidase alfa or any of its excipients. Caution is also advised for individuals with severe cardiac disease, uncontrolled respiratory failure, or significant renal impairment, as these conditions may increase the risk of serious adverse reactions.